NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Pharmaceutical POOL Melissa Barnes Anne Nobles Lilly Names New Ethics Chief Melissa Barnes has been promoted to chief ethics and compliance officer and senior VP president of enterprise risk management at Eli Lilly and Company. In her new role, Ms. Barnes reports to John Lechleiter, Ph.D., chairman, president, and CEO, and serves on the company’s executive committee. Ms. Barnes, who joined Lilly in 1994, replaces Anne Nobles, who has retired. Ms.?Barnes has served in a number of legal and business positions at Lilly, specializing in legal work related to compliance, litigation, human resources, regulatory, business management strategy, and global marketing and sales. Jeff HACKMAN Sigma-Tau Appoints VP of Commercial Operations Jeff Hackman has been appointed VP of commercial operations of Sigma-Tau Pharmaceuticals, the U.S. based, wholly owned subsidiary of the sigma-tau Group, which is dedicated to the global development and commercialization of medicines for patients with rare diseases. Most recently, at Intercell AG, Mr. Hackman served as the CEO of the U.S. office and global senior VP, commercial operations, where he managed the group global marketing and sales function. Biotechnology Pool Cynthia PaTTON Amgen Appoints Chief Compliance Officer Amgen, which discovers, develops, manufactures, and delivers innovative human therapeutics, has appointed Cynthia Patton senior VP and chief compliance officer. In this role, Ms. Patton is responsible for Amgen’s worldwide compliance and business ethics organization. Ms. Patton joined Amgen in 2005, and was most recently a VP in the Amgen law department with responsibility for commercial legal activities in the United States. Biopharma POOL Dr. Jeremy BENDER Dr. Aaron SATO Sutro Biopharma Expands Senior Management Team Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, has appointed Jeremy Bender, Ph.D., chief business officer, and Aaron Sato, Ph.D., VP of research. Most recently, Dr. Bender was VP, corporate development, of Allos Therapeutics. Before joining Sutro, Dr. Sato was senior director of antibody engineering at OncoMed Pharmaceuticals. Joanna Horobin Verastem Appoints Chief Medical Officer Verastem, a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, has appointed Joanna Horobin, M.B., Ch.B., as chief medical officer. Dr. Horobin was most recently the president of Syndax Pharmaceuticals. CRO POOL Dr. Susan Paulson Susan Seroskie Advanced Clinical Announces New Management Positions Advanced Clinical, a provider of clinical research solutions, has named Susan Paulson, Ph.D., as executive director, clinical pharmacology and nonclinical development. Dr. Paulson most recently ran her own consultancy, Paulson PK Consulting, which provided clinical pharmacology and nonclinical ADME expertise. In other company news, Susan Seroskie, was named executive VP, strategic resourcing. With more than 18 years of clinical development experience, Ms. Seroskie most recently was part of the senior leadership team for PharmaNet Development Group. Service POOL Glenn Bilawsky Precision Health Economics Names CEO Precision Health Economics (PHE), a healthcare consultancy, has named Glenn Bilawsky as CEO. Mr. Bilawsky served as CEO of the i3 division of UnitedHealth Group for more than eight years. PHE was formed in 2005 by Tomas Philipson, Dana Goldman, and Darius Lakdawalla, with the goal to use data-driven analysis tailored to each client’s strategic needs, and to improve public policy through insightful, issue-driven research. Dr. Susan Dallabrida PHT Appoints Senior Scientific Advisor Susan Dallabrida, Ph.D., has joined PHT Consulting Services as senior scientific advisor. She liaises with PHT clients and internal teams to expedite and expand PHT’s technology deliverables, and to facilitate study design. She brings more than 10 years of experience as a senior scientist and project director in R&D, clinical trial design and strategy, and product development to her new role. Rich Enz Comprehend Systems Adds to Management Team Comprehend Systems, a provider of cloud-based data analytics, visualizations, and reporting, has named Rich Enz as VP of quality assurance to support the development of pioneering cloud-based analytics tools. Before joining Comprehend, Mr. Enz served as associate director of application programming at Teva Pharmaceuticals. Dr. John LYNCH Cedarburg Hauser Appoints CSO Cedarburg Hauser Pharmaceuticals, a contract development and manufacturing organization, has appointed John Lynch, Ph.D., chief scientific officer. Dr. Lynch has served as Cedarburg Hauser’s director of R&D for the last three years, where he oversaw development projects and led a staff of scientists. Nick Willocks Symphony Appoints President Symphony, a global healthcare technology solutions provider, has appointed Nick Willocks as president. He is responsible for identifying and implementing new growth strategies. Most recently, Mr. Willocks was with McKinsey & Company. Agency POOL Robert Egert Jill Lesiak Michael Price Ogilvy CommonHealth Worldwide Promotes and Hires Ogilvy CommonHealth Worldwide, the health behavior experts of Ogilvy & Mather, have made several management promotions and hires at the organization’s NJ-based office. Robert Egert joins Ogilvy CommonHealth Interactive Marketing as a senior VP, managing director. In this position, he oversees the development of strategic digital marketing plans and manage client relations. Most recently, he was director of user experience and creative for Daniella Koren, a healthcare marketing firm. Jill Lesiak, with Ogilvy CommonHealth Payer Marketing for two years, has been promoted from VP, associate creative director, to VP creative director. In her new role, Ms. Lesiak continues to serve her assigned accounts, oversee copy output from her creative team, and lead promotional launch initiatives for a variety of therapeutic categories. Michael Price joins Ogilvy CommonHealth Medical Marketing as VP, account group supervisor. Mr. Price work as the account lead for his assigned brands, providing guidance and direction for upcoming product launches. Most recently, Mr. Price was an account director at Publicis Life Brands. Adrian SANSONE Publicis Life Brands Medicus Names New Managing Director Publicis Healthcare Communications Group (PHCG), one of the largest health-oriented agency networks in the world, has named Adrian Sansone as managing director, Publicis Life Brands Medicus (PLBM). PLBM is one of PHCG’s flagship agencies with offices in New York and Toronto. Most recently, Mr. Sansone served as general manager, Publicis Life Brands International, which is part of PLBM. use your QR?CODE?READER or go to bit.ly/PV0113-TalentPool Pharmaceutical Pool Dr. Flemming Ornskov Bayer Exec Takes Helm of Shire Flemming Ornskov, M.D., MBA, MPH, joins Shire as chief executive upon the retirement of Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry. Dr. Ornskov joins Shire from Bayer where, as chief marketing officer and global head, strategic marketing, for general and specialty medicine, he oversees the full pharmaceutical product portfolio, with sales in excess of 10 billion Euros from global marketing units in Europe, China, and the United States. Biotechnology Pool Dr. Alan LEWIS Medistem Names CEO Medistem, a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases, has appointed Dr. Alan Lewis as CEO and as a member of the board. Since January, Dr. Lewis has been functioning in the capacity of scientific advisory board member for Medistem. Most recently he was CEO of Ambit Biosciences. Dr. Elizabeth Trehu Promedior Appoints Chief Medical Officer Promedior, a clinical-stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, has appointed Elizabeth Trehu, M.D., as chief medical officer (CMO). As CMO, Dr. Trehu oversees all clinical development and regulatory activities for the company. Dr. Trehu was most recently VP of product development and medical affairs at Infinity Pharmaceuticals. Dr. Christian Weyer Fate Therapeutics Appoints President and CEO Christian Weyer, M.D., has been appointed president and CEO of Fate Therapeutics, which is pioneering innovative strategies to harness the therapeutic potential of adult stem cell biology, targeting disease areas of high unmet need. Dr. Weyer joins the company after a 12-year tenure with Amylin Pharmaceuticals, where he most recently served as senior VP of research and development until the completion of its acquisition by Bristol-Myers Squibb in August 2012. William Rastetter, a partner at Venrock who has served as Fate’s interim CEO since November 2011, will remain chairman of Fate’s board of directors. Biopharmaceutical Pool John Kaiser Dr. James Vornov Cerecor Announces Key Management Additions Cerecor, a biopharmaceutical company focused on the discovery, development, and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, has appointed John Kaiser and James Vornov, M.D., Ph.D., to its management team. Mr. Kaiser was named VP of commercialization and business development and is responsible for all commercial and business development efforts. Mr. Kaiser was most recently co-founder and CEO of Denysias Bioscience. Dr. Vornov, as senior VP, clinical development and regulatory affairs, is responsible for leading Cerecor’s clinical development strategy and program execution from human proof of concept through to product approval and commercialization. Before joining Cerecor, Dr. Vornov served as global therapeutic area leader, CNS at Parexel International. Dr. Brett Premack Celtaxsys Names Chief Technology Officer Celtaxsys, a private biopharma company developing a new class of drugs to treat inflammatory disorders through innate immunity, has appointed Brett Premack, Ph.D., chief technology officer. Most recently, Dr. Premack was VP, technology and strategic development, at Qu Biologics. Generic Pool Jill Desimone William Marth Allan Oberman Teva Announces Executive Changes Jill DeSimone has been named to the newly created position of senior VP and general manager of Teva Global Women’s Health, overseeing all aspects of Teva’s Women’s Health franchise. William Marth will step down as president and CEO of Teva Americas effective immediately and retire at the end of 2013. Mr. Marth will serve as a senior advisor to Dr. Jeremy Levin, president and CEO, of Teva until his retirement. Allan Oberman, senior VP of North America Generic Pharmaceuticals of Teva, has been appointed president and CEO of Teva Americas Generics as part of an orderly management succession. In this new role, Mr. Oberman will report directly to Dr. Levin, and have continued responsibility for North America Generics as well as overall management of Teva’s Latin American businesses. Device POOL Michael Mahoney New CEO and President of Boston Scientific Appointed Boston Scientific, as part of a planned succession strategy, has named Michael Mahoney as its new CEO and president. Mr. Mahoney, who succeeds interim CEO William (Hank) Kucheman, has also been appointed to the board of directors. Mr. Mahoney joined Boston Scientific as president in October 2011. For the past year, his responsibilities have focused on the oversight of cardiac rhythm management (CRM), endoscopy (GI and pulmonary), and numerous corporate functions. Service POOL Gerald Melillo Jr. PDI Names New President, Sales Services PDI, a healthcare commercialization company, has promoted Gerald Melillo Jr. to president, sales services, where he is responsible for the company’s sales operations. He previously served as senior VP of business development. Dr. Hans Winkler GNS Healthcare Expands Senior Management Team GNS Healthcare, a big data analytics company focused on enabling personalized medicine to improve human health, has named Hans Winkler, Ph.D., as chief scientific officer. Dr. Winkler is responsible for promoting the development of the company’s intellectual property, building product infrastructure, and fostering the overall scientific strategy for GNS’ product offerings to the pharmaceutical and biotechnology industry as well as academia. He was most recently senior director and global oncology biomarker program leader within Janssen Oncology Research and Development, a division of Johnson & Johnson. Cathy Wolfe Wolters Kluwer Health Appoints Medical Research President and CEO Wolters Kluwer Health, a global provider of information, business intelligence, and point-of-care solutions for the healthcare industry, has appointed Cathy Wolfe as president and CEO of its medical research business. A veteran of Wolters Kluwer, Ms. Wolfe has served as the CEO of Wolters Kluwer U.K. since 2007 and has been with the company since 1996, including key leadership positions in the United States and the United Kingdom. Agency POOL Frank Bartco Sarah Russe Discovery Chicago Promotes and Adds New Employees Frank Bartco has been promoted to VP, group account supervisor. In this role, he manages senior-level client contacts, leading the team in the use of new interactive programming tools, including tablet-based technologies, Webinars, and symposia. Sarah Russe has joined the Discovery Chicago team as a scientific director. She is responsible for leading the strategic development of promotional programs and materials that align to the brand goals and objectives. Marie Di Fiore Connexion Healthcare Hires Key Strategist Connexion Healthcare has added Marie DiFiore to its senior management team, as senior director of strategy and client services. Ms. DiFiore is responsible for the growth and enhancement of the rare diseases and neuroscience business units. Ms. DiFiore comes to the agency with 20 years of healthcare experience and clinical expertise in complex pharmaceuticals, biotherapeutics, and medical devices. Watson Pharmaceuticals has announced the global generics management team, following the completion of the acquisition of the Actavis Group. The combination creates the world’s third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenue in excess of $8 billion. “Since the announcement of our intention to acquire Actavis in April 2012, we have been working to ensure that we have the management structure in place to capitalize on the commercial momentum of this combined organization,” says Paul Bisaro, president and CEO of Watson. “Led by Siggi Olafsson, president, global generics, we begin operations as one company, with a commercial team that recognizes the extraordinary commercial expertise of senior leaders from both companies. We are structured to ensure that we immediately create value for customers and shareholders.” The combined company has operations in more than 60 countries, with a top 10 position in over 33 markets, including the U.S., U.K., Canada, Australia, Nordics, and Russia. The Company is also the fastest growing generic pharmaceutical company in Western Europe. The combined company will be geographically diverse, with about 40% of its generics revenue coming from outside of the United States. Watson will adopt a new global name — Actavis — effective in 2013. Global Generics Commercial Management Team Watson’s U.S. generic business, with about 10% U.S. market share, is being led by Andrew Boyer. Mr. Boyer joined Watson in 1998 as associate director of marketing in generics and has taken on roles with increasing responsibility, serving most recently as senior VP, sales and marketing. Watson’s Canada and Latin America business is being led by Jean-Guy Goulet. Mr. Goulet joined Watson in 2011 as president, Canada and Mexico for Watson’s Canadian subsidiary Cobalt Pharmaceuticals. Watson’s European generics business, led by Lars Ramneborn, has been structured into seven country clusters of about equal revenue size and with similar market structures and dynamics. Mr. Ramneborn was VP of strategy at Actavis, a position he held since March 2010. Watson’s Asia and Middle East and Africa (MEA) generics business, led by Hordur Thorhallsson, has been structured into five country clusters, based on geographic location as well as similarities in market structure and commercial dynamics. Mr. Thorhallsson was executive VP of MEA and Asia Pacific sales for Actavis. He joined the company in 2000. Watson’s Australian business is being led by Karen McTavish. Ms. McTavish joined Watson in 2012 to lead the company’s Australian business following the acquisition of Ascent Pharmaceuticals. Watson’s global generics R&D function is being headed by Hafrun Fridriksdottir, Ph.D. Dr. Fridriksdottir served most recently as Actavis’ VP of R&D, U.S., Europe and ROW, residing in the U.S. and serving on the company’s U.S. executive management board. Watson’s specialty pharmaceutical development function is being headed by Stefan Sveinsson, focusing on critical technologies for driving future product initiatives in both the global generics and global brands business. Mr. Sveinsson joined Actavis in 1993, serving most recently as executive VP of R&D. Wolter Kuizinga is leading Watson’s international business development function and Daniel Motto heads Watson’s U.S. business development function. Watson Announces Global Generics Management Team